Advertisement
Advertisement
BIO
Bio-Rad Laboratories, Inc.Class A
301.84
USDSponsored
+2.30
+0.77%
Feb 06, 16:00 UTC -5
Closed
After-Market
301.50
-0.34
-0.11%
BIO Earnings Reports
Positive Surprise Ratio
BIO beat 29 of 40 last estimates.
73%
Next Report
In 4 Days
Date of Next Report
Feb 12, 2026
Estimate for Q4 25 (Revenue/ EPS)
$700.89M
/$2.73
Implied change from Q3 25 (Revenue/ EPS)
+7.33%
/+21.33%
Implied change from Q4 24 (Revenue/ EPS)
+5.00%
/-5.86%
Bio-Rad Laboratories, Inc.Class A earnings per share and revenue
On Oct 29, 2025, BIO reported earnings of 2.25 USD per share (EPS) for Q3 25, beating the estimate of 1.95 USD, resulting in a 15.74% surprise. Revenue reached 653.00 million, compared to an expected 657.81 million, with a -0.73% difference. The market reacted with a -4.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of 2.73 USD, with revenue projected to reach 700.89 million USD, implying an increase of 21.33% EPS, and increase of 7.33% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Envista Holdings Corporation Common stock, $0.01 par value per share
Report Date
Feb 05, 2026 For Q4 25
Estimate
$0.32
Actual
$0.38
Surprise
+15.43%
Prestige Consumer Healthcare Inc.
Report Date
Feb 05, 2026 For Q3 26
Estimate
$1.15
Actual
$1.13
Surprise
-1.36%
Haemonetics Corporation
Report Date
Feb 05, 2026 For Q3 26
Estimate
$1.26
Actual
$1.31
Surprise
+3.75%
Stryker Corporation
Report Date
Jan 29, 2026 For Q4 25
Estimate
$4.43
Actual
$4.47
Surprise
+0.69%
Boston Scientific Corp.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.78
Actual
$0.80
Surprise
+1.61%
ResMed Inc.
Report Date
Jan 29, 2026 For Q2 26
Estimate
$2.75
Actual
$2.81
Surprise
+2.15%
GE HealthCare Technologies Inc. Common Stock
Report Date
Feb 04, 2026 For Q4 25
Estimate
$1.42
Actual
$1.44
Surprise
+0.96%
Phibro Animal Health Corporation Class A
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.68
Actual
$0.87
Surprise
+27.30%
Canopy Growth Corporation Common Shares
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.04
Actual
-$0.13
Surprise
-198.00%
Aurora Cannabis Inc. Common Shares
Report Date
Feb 04, 2026 For Q3 26
Estimate
$0.21
Actual
$0.12
Surprise
-42.72%
FAQ
What were Bio-Rad Laboratories, Inc.Class A's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Bio-Rad Laboratories, Inc.Class A reported EPS of $2.25, beating estimates by 15.74%, and revenue of $653.00M, -0.73% below expectations.
How did the market react to Bio-Rad Laboratories, Inc.Class A's Q3 2025 earnings?
The stock price moved down -4.65%, changed from $319.47 before the earnings release to $304.61 the day after.
When is Bio-Rad Laboratories, Inc.Class A expected to report next?
The next earning report is scheduled for Feb 12, 2026.
What are the forecasts for Bio-Rad Laboratories, Inc.Class A's next earnings report?
Based on 6
analysts, Bio-Rad Laboratories, Inc.Class A is expected to report EPS of $2.73 and revenue of $700.89M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement